Genetic Landscape in Women with Metastatic Ovarian Cancer Before and During Treatment with PARP Inhibitors

Launched by EUROPEAN INSTITUTE OF ONCOLOGY · Jan 17, 2025

Keywords

ClinConnect Summary

This clinical trial is investigating the genetic changes in women with advanced ovarian cancer who are receiving a treatment called PARP inhibitors. These medications are designed to help kill cancer cells, especially in patients with certain genetic mutations like BRCA1 or BRCA2, which affect how cells repair their DNA. The researchers want to understand how previous treatments, particularly chemotherapy, might lead to new genetic changes in the blood cells of these patients, which could increase the risk of developing additional blood disorders.

To participate in this trial, women must be between 65 and 74 years old and have advanced ovarian cancer that is either in complete or partial remission after surgery. They should also be eligible to start oral PARP inhibitors along with chemotherapy or as maintenance therapy. Participants will be monitored closely to see how their bodies respond to the treatment and to gather important information about their genetic makeup. It’s crucial for potential participants to know that those with specific blood cell count issues or significant cancer in their bone marrow will not be eligible for this study.

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • Women with advanced ovarian cancer in complete or partial remission after surgery and eligible to oral PARP inhibitors as first line in association to chemotherapy or as maintenance therapy.
• Exclusion Criteria:
• • Presence of blood cell count abnormalities before PARP inhibitor treatment;
• • Bone marrow infiltration by EOC cells.